Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Breast Cancer Res Treat. 2019 Feb 23;175(2):327–337. doi: 10.1007/s10549-019-05161-8

Fig. 1.

Fig. 1

4OHT Acts as an Agonist in ER+ ILC Cells. a SNAI1 qRT-PCR assessment of ILC (red) and IDC (blue) cells was performed at 24 hours post deprivation/treatments (Vehicle 0.1% DMSO). Quantifications are a representative single experiment ± STDEV of technical triplicates, with similar results in two additional independently performed experiments. Asterisks depict significance compared to Vehicle from One Way ANOVA followed by Tukey’s post-test. b RPPA analysis of MDA-MB-134-VI and Sum44PE cells in Full Serum (FS) or deprived of exogenous estrogens (Cont) followed by treatment with 1 nM E2 for 24 hours. Top ten E2-upregulated and downregulated proteins in MDA-MB-134-VI cells are displayed. Log2 fold change (FC) for SNAIL is depicted in the table. (C) SNAIL immunoblots were performed in MDA-MB-134-VI and Sum44PE cells at 24 hours post deprivation/treatments. Representative images are displayed (top) along with quantification of band intensities (bottom). Graphs represent mean +/− standard error relative to Vehicle from independent experiments (n=3). Asterisks depict significance compared to Vehicle from One Way ANOVA followed by Dunnett’s post-test. (*p<0.05, **p<0.005, ***p<0.0005)